Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 11-valent HPV Vaccine in Chinese Women
NCT04083196Phase 1Completed
- Sponsor
- Serum Institute of India
- Start
- Sep 2019
- Primary completion
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 11-valent recombinant human papilloma virus vaccine in human papillomavirus infection and cervical carcinoma (2 arms), sponsored by Serum Institute of India. Primary endpoints: Adverse Events of local and systemic reactions, All active Adverse Events at 7 days and 2 more. Started Sep 2019; status: completed.
02
Drugs
11-valent recombinant human papilloma virus vaccine
03
Conditions
human papillomavirus infectioncervical carcinoma
Beyond the preview
Go deeper on NCT04083196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083196.